Short Interest in Akari Therapeutics, Plc (NASDAQ:AKTX) Drops By 94.3%

Akari Therapeutics, Plc (NASDAQ:AKTX) saw a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 600 shares, a decrease of 94.3% from the March 31st total of 10,500 shares. Based on an average daily volume of 12,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the shares of the company are short sold.

Institutional Trading of Akari Therapeutics

A hedge fund recently raised its stake in Akari Therapeutics stock. Omnia Family Wealth LLC raised its holdings in Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 87,628 shares of the biopharmaceutical company’s stock after acquiring an additional 28,511 shares during the period. Omnia Family Wealth LLC owned approximately 1.55% of Akari Therapeutics worth $273,000 at the end of the most recent quarter. 5.06% of the stock is owned by institutional investors and hedge funds.

Akari Therapeutics Price Performance

Shares of AKTX stock remained flat at $1.19 during mid-day trading on Thursday. 3,902 shares of the stock traded hands, compared to its average volume of 12,181. The stock’s 50-day moving average price is $1.82 and its two-hundred day moving average price is $2.63. Akari Therapeutics has a twelve month low of $1.08 and a twelve month high of $5.50.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Akari Therapeutics in a research note on Wednesday. They set a “sell” rating on the stock.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.